11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite global reductions in HIV incidence and mortality, the 15 UNAIDS-designated countries of Eastern Europe and Central Asia (EECA) that gained independence from the Soviet Union in 1991 constitute the only region where both continue to rise. HIV transmission in EECA is fuelled primarily by injection of opioids, with harsh criminalisation of drug use that has resulted in extraordinarily high levels of incarceration. Consequently, people who inject drugs, including those with HIV, hepatitis C virus, and tuberculosis, are concentrated within prisons. Evidence-based primary and secondary prevention of HIV using opioid agonist therapies such as methadone and buprenorphine is available in prisons in only a handful of EECA countries (methadone or buprenorphine in five countries and needle and syringe programmes in three countries), with none of them meeting recommended coverage levels. Similarly, antiretroviral therapy coverage, especially among people who inject drugs, is markedly under-scaled. Russia completely bans opioid agonist therapies and does not support needle and syringe programmes—with neither available in prisons—despite the country’s high incarceration rate and having the largest burden of people with HIV who inject drugs in the region. Mathematical modelling for Ukraine suggests that high levels of incarceration in EECA countries facilitate HIV transmission among people who inject drugs, with 28–55% of all new HIV infections over the next 15 years predicted to be attributable to heightened HIV transmission risk among currently or previously incarcerated people who inject drugs. Scaling up of opioid agonist therapies within prisons and maintaining treatment after release would yield the greatest HIV transmission reduction in people who inject drugs. Additional analyses also suggest that at least 6% of all incident tuberculosis cases, and 75% of incident tuberculosis cases in people who inject drugs are due to incarceration. Interventions that reduce incarceration itself and effectively intervene with prisoners to screen, diagnose, and treat addiction and HIV, hepatitis C virus, and tuberculosis are urgently needed to stem the multiple overlapping epidemics concentrated in prisons.

          Related collections

          Author and article information

          Journal
          2985213R
          5470
          Lancet
          Lancet
          Lancet (London, England)
          0140-6736
          1474-547X
          16 October 2016
          14 July 2016
          17 September 2016
          31 October 2016
          : 388
          : 10050
          : 1228-1248
          Affiliations
          School of Medicine and School Public Health, Yale University, New Haven, CT, USA (Prof F L Altice MD); Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK (L Azbel MSc); School of Social and Community Medicine, Bristol University, Bristol, UK (J Stone MMathStat, E Brooks-Pollock PhD, N K Martin, Prof P Vickerman DPhil); ICF International Alliance for Public Health, Kiev, Ukraine (P Smyrnov MPH); Ukrainian Institute on Public Health Policy, Kiev, Ukraine (S Dvoriak MD); Department of Criminology, Law and Society, George Mason University, Fairfax, VA, USA (Prof F S Taxman PhD); School of Social Work, Columbia University, New York, NY, USA (Prof N El-Bassel PhD); Division of Global Public Health, University of California San Diego, San Diego, CA, USA (N K Martin DPhil); Department of Psychiatry, University of Colorado, Denver, CO, USA (Prof R Booth PhD); Institute of Addiction Research, Frankfurt University of Applied Sciences, Frankfurt, Germany (Prof H Stöver PhD); and National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia (Prof K Dolan PhD)
          Author notes
          Correspondence to: Prof Frederick L Altice, School of Medicine and School of Public Health, Yale University, New Haven, CT 06510-2283, USA, frederick.altice@ 123456yale.edu
          Article
          PMC5087988 PMC5087988 5087988 nihpa823342
          10.1016/S0140-6736(16)30856-X
          5087988
          27427455
          e0b08f9b-407c-45ce-88b6-00746ce590a1
          History
          Categories
          Article

          Comments

          Comment on this article